Literature DB >> 32591907

Antiresorptive agents-related osteonecrosis of the jaw (ARONJ) in rheumatoid arthritis.

Yuichiro Fujieda1, Tatsuya Atsumi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32591907     DOI： 10.1007/s00774-020-01112-2

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN： 0914-8779            Impact factor:   2.626


× No keyword cloud information.
  2 in total

1.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Authors:  F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey
Journal:  Ann Oncol       Date:  2011-10-10       Impact factor: 32.976

2.  Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

Authors:  Alison T Stopeck; Karim Fizazi; Jean-Jacques Body; Janet E Brown; Michael Carducci; Ingo Diel; Yasuhiro Fujiwara; Miguel Martín; Alexander Paterson; Katia Tonkin; Neal Shore; Paul Sieber; Frank Kueppers; Lawrence Karsh; Denise Yardley; Huei Wang; Tapan Maniar; Jorge Arellano; Ada Braun
Journal:  Support Care Cancer       Date:  2015-09-03       Impact factor: 3.603
  2 in total
  1 in total

1.  High incidence of antiresorptive agent-related osteonecrosis of the jaw in patients with rheumatoid arthritis.

Authors:  Ryu Watanabe
Journal:  J Bone Miner Metab       Date:  2020-04-09       Impact factor: 2.626
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.